Merck Serono
{{Short description|German pharmaceutical company}}
{{Use dmy dates|date=March 2025}}
| class="toccolours" style="float: right; margin: 0 0 1em 1em; width: 20em; font-size: 90%; clear:right;" cellspacing="5" |
| colspan="2" style="text-align: center; font-size: larger;" | Merck Serono |
|---|
| colspan="2" style="text-align: center; font-size: larger;" | EMD Serono |
| colspan="2" style="padding: 1em 0; text-align: center;" | |
| style="vertical-align: top; text-align: left;"
| Type | Stock corporation |
| style="vertical-align: top; text-align: left;"
| Founded | 1668 |
| style="vertical-align: top; text-align: left;"
|Location | Darmstadt, Germany (Headquarters) |
| style="vertical-align: top; text-align: left;"
|Key people |
| style="vertical-align: top; text-align: left;" |
| style="vertical-align: top; text-align: left;"
| Rebif, Mavenclad, Gonal-f, Luveris, Ovidrel/Ovitrelle, Serostim, Saizen, Zorbtive, Erbitux and Bavencio |
| style="vertical-align: top; text-align: left;"
| USD ~5 billion (projected) |
| style="vertical-align: top; text-align: left;"
| {{URL|http://www.merckserono.com/}} |
File:01337LOW HQ MERCK SERONO.jpg).]]
Merck Serono (EMD Serono in the United States and Canada) is a pharmaceutical company headquartered in Darmstadt, Germany, and a brand and division of Merck focused on biopharmaceuticals.[http://www.merckserono.com/en/about_us/index.html Background Info], www.merckserono.com
In September 2006, Merck KGaA announced its intent to purchase the majority of Serono shares from Ernesto Bertarelli and the Bertarelli family. The Merck-Serono merger was announced on 21 September 2006. Merck KGaA and Serono operated as distinct entities until at least January 2007. As of 5 January 2007, Merck held the majority shares of Serono. The new company is called Merck Serono international SA. In 2012, Merck Serono moved its headquarters from Geneva, Switzerland to Darmstadt.
Drugs they market include Erbitux, UFT, Rebif, Mavenclad, Novantrone, Gonal, Ovidrel/Ovitrelle, Zorbtive, Luveris, Saizen, Serostim, Glucophage, Concor and Euthyrox. Raptiva was withdrawn in 2007.
In the U.S. and Canada, Merck Serono is known as EMD Serono, as the former Merck subsidiary Merck & Co. holds the rights to the name Merck in those countries.
Collaborative research
In addition to internal research and development activities Merck Serono with the help of Toledana, is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.{{Cite book| last1 = Mattes | first1 = William B.| chapter = Public Consortium Efforts in Toxicogenomics | doi = 10.1007/978-1-60327-048-9_11 | title = Essential Concepts in Toxicogenomics| editor1-last = Mendrick | editor1-first = Donna L.| editor2-last = Mattes | editor2-first = William B.| series = Methods in Molecular Biology| volume = 460 | pages = 221–238 | year = 2008 | isbn = 978-1-58829-638-2 | pmid = 18449490 }}{{cite web|url=http://www.innomed-predtox.com/consortium/members/ |title=InnoMed PredTox Member Organizations |access-date=2008-08-25 |url-status=dead |archive-url=https://web.archive.org/web/20080926214522/http://www.innomed-predtox.com/consortium/members/ |archive-date=26 September 2008 }} The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.{{cite web|url=http://imi.europa.eu/docs/calls01_en.zip|title=IMI Call Topics 2008|last=Innovative Medicines Initiative|work=IMI-GB-018v2-24042008-CallTopics.pdf|publisher=European Commission|access-date=2008-08-25|archive-url=https://web.archive.org/web/20091015122459/http://imi.europa.eu/docs/calls01_en.zip|archive-date=15 October 2009|url-status=dead}}
Notes and references
{{Reflist}}
See also
External links
{{Commons category|Merck Serono}}
- [http://www.merckserono.com Merck Serono company website]
- [http://www.emdserono.com EMD Serono]
{{Merck Serono|state=autocollapse}}
{{Merck Group|state=autocollapse}}
{{Portal bar|Companies|Germany}}
{{Authority control}}